Literature DB >> 18382632

Prenatal Screening for HIV in Nova Scotia: Survey of Postpartum Women and Audit of Current Prenatal Screening Practices.

Mark Downing1, Laura Youden, Beth A Halperin, Heather Scott, Bruce Smith, Scott A Halperin.   

Abstract

BACKGROUND: Current guidelines for screening for HIV infections in Nova Scotia recommend an opt-in approach in which patients are counselled and consent to testing. The objectives of the present study were to measure adherence to these recommendations, to explore women's knowledge, attitudes, beliefs and behaviours concerning HIV screening, and to compare these results with prenatal screening practices for rubella, hepatitis B and group B streptococcus.
METHODS: All women who gave birth consecutively during a seven-week period were recruited. Study participants were interviewed to determine their knowledge, attitudes and beliefs concerning prenatal screening. Hospital and laboratory records were reviewed for information concerning prenatal screening and perinatal treatment to audit screening practices.
RESULTS: A total of 279 patients were enrolled in the study, representing 58% of those eligible. The HIV screening rate was 72%, compared with 95% for rubella, 89% for hepatitis B and 24% for group B streptococcus. Of the participants tested for HIV, 80% were aware of being tested. Of all the study participants, 17% indicated having received pretest counselling about HIV, 56% volunteered to be tested for HIV, 78% received the test results, and 3.8% received post-test counselling. More participants preferred an opt-out approach to HIV screening (50%), where testing is routinely performed on everyone, rather than the opt-in approach (43%). Participants displayed a similar preference for screening for the other infections.
INTERPRETATION: HIV prenatal testing rates in Nova Scotia are comparable with those of other provinces that recommend an opt-in approach, but are lower than testing rates for opt-out programs. Most study participants were not screened using the recommended opt-in approach.

Entities:  

Keywords:  HIV antibodies; Mass screening; Pregnancy; Prenatal screening; Survey

Year:  2006        PMID: 18382632      PMCID: PMC2095076          DOI: 10.1155/2006/195842

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  19 in total

Review 1.  Opt in or opt out: what is optimal for prenatal screening for HIV infection?

Authors:  Sharon Walmsley
Journal:  CMAJ       Date:  2003-03-18       Impact factor: 8.262

2.  Apparent vertical transmission of human immunodeficiency virus type 1 by breast-feeding in Zambia.

Authors:  S K Hira; U G Mangrola; C Mwale; C Chintu; G Tembo; W E Brady; P L Perine
Journal:  J Pediatr       Date:  1990-09       Impact factor: 4.406

3.  Testing for human immunodeficiency virus type 1 (HIV-1) infection in pregnancy.

Authors: 
Journal:  Paediatr Child Health       Date:  2001-11       Impact factor: 2.253

4.  Mother-to-infant transmission of human immunodeficiency virus type 1: association with prematurity or low anti-gp120.

Authors:  J J Goedert; H Mendez; J E Drummond; M Robert-Guroff; H L Minkoff; S Holman; R Stevens; A Rubinstein; W A Blattner; A Willoughby
Journal:  Lancet       Date:  1989-12-09       Impact factor: 79.321

5.  Transplacental transmission of human immunodeficiency virus.

Authors:  H di Maria; C Courpotin; C Rouzioux; D Cohen; D Rio; F Boussin; D Dormont
Journal:  Lancet       Date:  1986-07-26       Impact factor: 79.321

6.  Transplacental transmission of HTLV-III virus.

Authors:  N Lapointe; J Michaud; D Pekovic; J P Chausseau; J M Dupuy
Journal:  N Engl J Med       Date:  1985-05-16       Impact factor: 91.245

7.  HIV testing among pregnant women--United States and Canada, 1998-2001.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-11-15       Impact factor: 17.586

8.  Evidence-based guidelines for universal counselling and offering of HIV testing in pregnancy in Canada.

Authors:  L Samson; S King
Journal:  CMAJ       Date:  1998-06-02       Impact factor: 8.262

9.  Routine prenatal screening for HIV in a low-prevalence setting.

Authors:  D M Patrick; D M Money; J Forbes; S R Dobson; M L Rekart; D A Cook; P J Middleton; D R Burdge
Journal:  CMAJ       Date:  1998-10-20       Impact factor: 8.262

10.  Risk factors for mother-to-child transmission of HIV-1.

Authors: 
Journal:  Lancet       Date:  1992-04-25       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.